A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression - Dominguez-Mozo, Maria Inmaculada; Galán, Victoria; Ramió-Torrentà, Lluís; Quiroga, Ana; Quintana, E.; Villar, Luisa María; Costa-Frossard, Lucienne; Fernández-Velasco, José Ignacio; Villarrubia, Noelia; Garcia-Martinez, María Angel; Arroyo, Rafael; Alvarez-Lafuente, Roberto (Frontiers in immunology, 2024)
Keywords: Adult; Disease Progression; Epstein-Barr virus; Epstein-Barr Virus Nuclear Antigens - immunology; Female; fingolimod; Fingolimod Hydrochloride - therapeutic use; human herpesvirus 6; human leukocyte antigen; Humans; Immunoglobulin G - blood; Immunology; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; multiple sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Multiple Sclerosis, Relapsing-Remitting - blood; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - immunology; Retrospective Studies; Treatment Outcome; human herpesvirus 6; Epstein-Barr virus; human leukocyte antigen; fingolimod; multiple sclerosis